Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Interleukin 2”

468 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 468 results

Testing effectiveness (Phase 2)Study completedNCT00040586
What this trial is testing

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Who this might be right for
Prostatic Neoplasms
BZL Biologics
Testing effectiveness (Phase 2)Study completedNCT00001566
What this trial is testing

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

Who this might be right for
Ewing's SarcomaRhabdomyosarcoma
National Cancer Institute (NCI) 42
Early research (Phase 1)Study completedNCT00016237
What this trial is testing

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Who this might be right for
Bladder CancerKidney CancerLung Cancer
EMD Serono
Testing effectiveness (Phase 2)Looking for participantsNCT07646639
What this trial is testing

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

Who this might be right for
Rectal CancerRadiotherapy
The First Affiliated Hospital with Nanjing Medical University 122
Testing effectiveness (Phase 2)Study completedNCT03113773
What this trial is testing

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Who this might be right for
Ischemic Heart Disease
Cambridge University Hospitals NHS Foundation Trust 41
Testing effectiveness (Phase 2)Ended earlyNCT02389231
What this trial is testing

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment

Who this might be right for
Autoimmune Hemolytic Anemia
University Hospital, Bordeaux 2
Testing effectiveness (Phase 2)UnknownNCT02340845
What this trial is testing

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

Who this might be right for
Cancer
Oeyama-Moto Cancer Research Foundation 100
Testing effectiveness (Phase 2)WithdrawnNCT02997150
What this trial is testing

Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study

Who this might be right for
Nephrotic Syndrome Steroid-DependentInterleukin 2
University Hospital, Limoges
Not applicableEnded earlyNCT05471271
What this trial is testing

IL-2 PET Imaging in Advanced Solid Tumours

Who this might be right for
Metastatic Solid Tumor
University Medical Center Groningen 1
Testing effectiveness (Phase 2)UnknownNCT01274273
What this trial is testing

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Who this might be right for
Metastatic Renal Cell Carcinoma
University of Aarhus 118
Early research (Phase 1)Study completedNCT00019175
What this trial is testing

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Who this might be right for
Melanoma (Skin)
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT01032681
What this trial is testing

EMD 521873 in Advanced Solid Tumors, MTD Finding

Who this might be right for
Non-Hodgkin Lymphoma
Merck KGaA, Darmstadt, Germany 66
Testing effectiveness (Phase 2)Study completedNCT04856930
What this trial is testing

Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Who this might be right for
Hidradenitis Suppurativa
Vanda Pharmaceuticals 149
Large-scale testing (Phase 3)Study completedNCT00006363
What this trial is testing

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Erythroid Leukemia (M6)+30 more
National Cancer Institute (NCI) 720
Testing effectiveness (Phase 2)UnknownNCT00604136
What this trial is testing

Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy

Who this might be right for
Metastatic Melanoma
Hadassah Medical Organization 20
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Looking for participantsNCT04643002
What this trial is testing

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Who this might be right for
Plasma Cell Myeloma Refractory
Sanofi 258
Large-scale testing (Phase 3)Study completedNCT00018941
What this trial is testing

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Who this might be right for
Kidney Cancer
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT00058786
What this trial is testing

Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells

Who this might be right for
Chronic Lymphocytic B-Leukemia
Baylor College of Medicine 9
Early research (Phase 1)Study completedNCT04695327
What this trial is testing

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

Who this might be right for
Solid Tumor
TILT Biotherapeutics Ltd. 32
Next Page